Prab: CSV import

2025-03-05T06:12:44Z

CSV import

← Older revision		Revision as of 06:12, 5 March 2025
Line 3:		Line 3:
	\| verifiedfields = changed		\| verifiedfields = changed
	\| verifiedrevid = 123456789		\| verifiedrevid = 123456789
	\| IUPAC_name = (2S)-2-[[4-(5-chloro-2-methylphenyl)piperazin-1-yl]methyl]-N-[(2S)-1-~~oxo~~-~~3-phenyl-1,~~2~~,3,4~~-~~tetrahydroisoquinolin~~-2-yl]butanamide		\| IUPAC_name = (2S)-2-[[4-(5-chloro-2-methylphenyl)piperazin-1-yl]methyl]-N-[(2S)-1-methyl-2-phenylpropan-2-yl]butanamide
	\| image = JNJ-61393215.svg		\| image = JNJ-61393215.svg
	\| image2 =		\| image2 =
Line 11:		Line 11:
	}}		}}

	'''Tebideutorexant''' is a [[dual orexin receptor antagonist]] (DORA) ~~that is being investigated~~ for ~~its potential use in~~ the treatment of [[insomnia]] and other sleep disorders. It is ~~known~~ by ~~its developmental code name '''JNJ-61393215'''~~.		'''Tebideutorexant''' (development code '''JNJ-61393215''') is a [[dual orexin receptor antagonist]] (DORA) under investigation for the treatment of [[insomnia]] and other sleep disorders. It is being developed by [[Janssen Pharmaceuticals]], a subsidiary of [[Johnson & Johnson]].

	==Mechanism of Action==		==Mechanism of Action==
	Tebideutorexant functions by selectively blocking the activity of the [[orexin]] neuropeptides, which are involved in the regulation of the sleep-wake cycle. Orexins, also known as hypocretins, are produced in the [[hypothalamus]] and promote wakefulness. By antagonizing the [[orexin receptor~~\|orexin receptors~~]] ~~OX1~~ and ~~OX2~~, tebideutorexant reduces wakefulness and facilitates the onset and maintenance of sleep.		Tebideutorexant functions by selectively blocking the activity of the [[orexin]] neuropeptides, which are involved in the regulation of the sleep-wake cycle. Orexins, also known as hypocretins, are produced in the [[hypothalamus]] and promote wakefulness. By antagonizing the [[orexin receptor]]s OX1R and OX2R, tebideutorexant reduces wakefulness and facilitates the onset and maintenance of sleep.

	==Pharmacokinetics==		==Pharmacokinetics==
	Tebideutorexant is designed to have a favorable pharmacokinetic profile, with a rapid onset of action and a ~~duration~~ that supports ~~sleep throughout the night without causing residual sedation the following day~~. The drug is metabolized primarily in the liver and excreted ~~via~~ the kidneys.		Tebideutorexant is designed to have a favorable pharmacokinetic profile, with a rapid onset of action and a half-life that supports once-daily dosing. The drug is metabolized primarily in the liver and excreted through the kidneys. Its pharmacokinetic properties are optimized to minimize next-day residual effects, a common concern with sleep medications.

	==Clinical Development==		==Clinical Development==
	Tebideutorexant is currently undergoing clinical trials to evaluate its efficacy and safety in patients with insomnia. ~~Preliminary~~ studies have shown promising results~~, with improvements~~ in sleep ~~onset~~ and maintenance ~~compared~~ to ~~placebo~~.		Tebideutorexant is currently undergoing clinical trials to evaluate its efficacy and safety in patients with insomnia. Early-phase studies have shown promising results in terms of sleep induction and maintenance, with a side effect profile that is generally well-tolerated. The ongoing trials aim to further establish the therapeutic potential of tebideutorexant in comparison to existing treatments.

	==Potential Benefits==		==Potential Benefits==
	~~As a dual orexin receptor antagonist,~~ tebideutorexant ~~offers~~ a ~~novel approach~~ to ~~treating~~ insomnia~~, particularly for patients who do not respond well to~~ traditional [[~~benzodiazepine~~]] or [[non-benzodiazepine]] ~~hypnotics~~. ~~Its mechanism of action allows for~~ a ~~more natural sleep architecture~~, ~~potentially reducing the~~ risk of ~~dependence~~ and ~~other side effects associated with other sleep medications~~.		The development of tebideutorexant is part of a broader effort to provide new treatment options for insomnia that have fewer side effects than traditional [[benzodiazepines]] and [[non-benzodiazepine]] sleep aids. As a DORA, tebideutorexant may offer advantages such as reduced risk of dependency and a lower incidence of cognitive impairment.

	==Related ~~pages~~==		==Related Pages==
	* [[Orexin receptor antagonist]]		* [[Orexin receptor antagonist]]
	* [[Insomnia]]		* [[Insomnia]]
	* [[Sleep disorder]]		* [[Sleep disorder]]
			* [[Janssen Pharmaceuticals]]

	[[Category:Orexin receptor antagonists]]		[[Category:Orexin receptor antagonists]]
	[[Category:Experimental drugs]]		[[Category:Experimental drugs]]
			[[Category:Sleep disorders]]

Prab: CSV import

2025-03-04T21:36:16Z

CSV import

New page

{{Short description|A dual orexin receptor antagonist}}
{{Drugbox
| verifiedfields = changed
| verifiedrevid = 123456789
| IUPAC_name = (2S)-2-[[4-(5-chloro-2-methylphenyl)piperazin-1-yl]methyl]-N-[(2S)-1-oxo-3-phenyl-1,2,3,4-tetrahydroisoquinolin-2-yl]butanamide
| image = JNJ-61393215.svg
| image2 =
| width = 200
| alt =
| caption = Chemical structure of Tebideutorexant
}}

'''Tebideutorexant''' is a [[dual orexin receptor antagonist]] (DORA) that is being investigated for its potential use in the treatment of [[insomnia]] and other sleep disorders. It is known by its developmental code name '''JNJ-61393215'''.

==Mechanism of Action==
Tebideutorexant functions by selectively blocking the activity of the [[orexin]] neuropeptides, which are involved in the regulation of the sleep-wake cycle. Orexins, also known as hypocretins, are produced in the [[hypothalamus]] and promote wakefulness. By antagonizing the [[orexin receptor|orexin receptors]] OX1 and OX2, tebideutorexant reduces wakefulness and facilitates the onset and maintenance of sleep.

==Pharmacokinetics==
Tebideutorexant is designed to have a favorable pharmacokinetic profile, with a rapid onset of action and a duration that supports sleep throughout the night without causing residual sedation the following day. The drug is metabolized primarily in the liver and excreted via the kidneys.

==Clinical Development==
Tebideutorexant is currently undergoing clinical trials to evaluate its efficacy and safety in patients with insomnia. Preliminary studies have shown promising results, with improvements in sleep onset and maintenance compared to placebo.

==Potential Benefits==
As a dual orexin receptor antagonist, tebideutorexant offers a novel approach to treating insomnia, particularly for patients who do not respond well to traditional [[benzodiazepine]] or [[non-benzodiazepine]] hypnotics. Its mechanism of action allows for a more natural sleep architecture, potentially reducing the risk of dependence and other side effects associated with other sleep medications.

==Related pages==
* [[Orexin receptor antagonist]]
* [[Insomnia]]
* [[Sleep disorder]]

[[Category:Orexin receptor antagonists]]
[[Category:Experimental drugs]]

Tebideutorexant - Revision history

Prab: CSV import

Prab: CSV import